EH

Experimental Hematology & Oncology

Experimental Hematology & Oncology publishes preclinical, basic, patient-oriented and translational research in all areas of hematology and oncology. The journal serves as an international platform for laboratory findings and publishes clinical trials with negative results as well as basic science studies with provocative findings. It is a peer-reviewed open access journal with a reported time to first decision of less than 30 days.

Looking to publish in Experimental Hematology & Oncology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now
Subject Hematology, Oncology
Impact Factor 13.5
Quartile Q1
Open Access Type Open
eISSN 2162-3619
Invitation Only Yes
Cost Range Authors are asked to pay an open access fee for open access publication; article processing charges and book processing charges apply.

Submission Instructions

Experimental Hematology & Oncology is an invitation-only journal. Submissions are accepted by invitation from the editorial board only. The following article types are accepted:

Research Article

Cover Letter A cover letter is required. Cover letter must explain why the manuscript should be published, address any issues relating to journal policies, declare any potential competing interests, confirm all authors approved the submission, and confirm the manuscript has not been published or submitted elsewhere.
Abstract An abstract is required. Abstract must not exceed 350 words. Abstract must be structured. Abstract must include the headings Background, Methods, Results, and Conclusions, and Research Articles reporting health care interventions on human participants must also include a Trial registration section.
Manuscript Manuscript must include a title page, Methods, Results, Discussion, Conclusions, a Declarations section, and a list of abbreviations if abbreviations are used. Manuscript must provide three to ten keywords, include Declarations subheadings for Ethics approval and consent to participate, Consent for publication, Availability of data and materials, Competing interests, Funding, Authors' contributions, and Acknowledgements with 'Not applicable' where irrelevant, and document any use of a Large Language Model in the Methods section or suitable alternative.
References References must use Vancouver style. Only published, in-press, or publicly available e-print or preprint sources may be cited, unpublished abstracts, unpublished data, and personal communications must not appear in the reference list, journal abbreviations must follow Index Medicus/MEDLINE, and all URLs must be numbered and included in the reference list with full site title, URL, and access date.
Figures & Tables Figure titles and legends must be provided in the main manuscript while figures are uploaded separately, and tables larger than one page may be placed at the end of the manuscript with their intended placement indicated in the text. Figures must be numbered in order of first mention and multi-panel figures submitted as a single composite file, while tables must be numbered and cited in sequence and must not be embedded as figures or spreadsheet files.
Reformat to Experimental Hematology & Oncology using Livewrite Premium

Review

Cover Letter A cover letter is required. The cover letter must explain why the manuscript should be published in Experimental Hematology & Oncology, address any journal policy issues, declare any potential competing interests, confirm all authors approved submission, and confirm the manuscript has not been published or submitted elsewhere.
Abstract An abstract is required. The abstract must not exceed 350 words. The abstract must be structured. The abstract must include Background, Main body, and short Conclusion sections.
Manuscript The manuscript must include a title page, Background, Main text, Conclusions, and a Declarations section. The manuscript must include three to ten keywords, a list of abbreviations if abbreviations are used, documentation of any Large Language Model use in the Methods or another suitable section, and Declarations subheadings including Availability of data and materials, Competing interests, Funding, Authors' contributions, Acknowledgements, and optional Authors' information with nonrelevant sections marked 'Not applicable'.
References References must follow the Vancouver reference style. Only published, in-press, or publicly available e-print or preprint articles, clinical trial registration records, and abstracts may be cited; unpublished abstracts, unpublished data, and personal communications must not appear in the reference list, journal abbreviations must follow Index Medicus/MEDLINE, and web links must be numbered and included in the reference list with full site title, URL, and access date.
Figures & Tables Figure titles and legends must be provided in the main manuscript rather than in the graphic file, and figures must be uploaded separately in the order first cited in the text. Multi-panel figures must be submitted as a single composite file, and tables must be created with the word processor's table function rather than embedded as figures or spreadsheet files.
Reformat to Experimental Hematology & Oncology using Livewrite Premium

Correspondence

Cover Letter A cover letter is required. Cover letter must explain why the manuscript should be published, address any issues relating to journal policies, declare any potential competing interests, confirm all authors approved the submission, and confirm the content has not been published or submitted elsewhere.
Abstract An abstract is required. Abstract must not exceed 250 words. Abstract must be one paragraph and unstructured. Abstract must briefly summarize the aim, findings, or purpose of the article and must not cite references.
Manuscript Main text must not exceed 700 words. Main text must start with "To the editor" and may be broken into subsections with short, informative headings. Manuscript must include three to ten keywords and a Declarations section with the subheadings Ethics approval and consent to participate, Consent for publication, Availability of data and materials, Competing interests, Funding, Authors' contributions, Acknowledgements, and Authors' information (optional), with non-relevant headings marked "Not applicable".
References References must not exceed 12. References must follow Vancouver reference style. Journal abbreviations must follow Index Medicus/MEDLINE, web links and URLs must be included in the reference list with a reference number, and unpublished abstracts, unpublished data, and personal communications must not be included in the reference list.
Figures & Tables A maximum of two figures or two tables, or one figure plus one table, is permitted. Figure titles and legends must be provided in the main manuscript, and figures must be uploaded separately in the order they are first mentioned in the text. Multi-panel figures must be submitted as a single composite file, and tables must be numbered and cited in sequence using Arabic numerals.
Reformat to Experimental Hematology & Oncology using Livewrite Premium

Case Report

Cover Letter A cover letter is required for Case Reports. The cover letter should describe why the case is rare or unusual, its educational and/or scientific merits, why the manuscript should be published in the journal, any issues relating to journal policies, any potential competing interests, and confirmation that all authors approved the submission.
Abstract An abstract is required for Case Reports. The abstract must not exceed 350 words. The abstract must be structured. The abstract must include the headings Background, Case presentation, and Conclusions.
Manuscript The manuscript must include Background, Case presentation, Discussion and Conclusions, and a Declarations section. The manuscript must include three to ten keywords and a Declarations section with the subheadings Ethics approval and consent to participate, Consent for publication, Availability of data and materials, Competing interests, Funding, Authors' contributions, and Acknowledgements, using 'Not applicable' for any irrelevant section.
References References must use Vancouver style. Journal abbreviations must follow Index Medicus/MEDLINE, only published or publicly available articles, clinical trial registration records, and abstracts may be cited, unpublished abstracts, unpublished data, and personal communications must not appear in the reference list, and all web links and URLs must be numbered and included in the reference list in full with title, URL, and access date.
Figures & Tables Figure titles and legends must be provided in the main manuscript rather than in the graphic file, and tables larger than one page may be placed at the end of the manuscript with their intended position indicated in the text. Figures and tables must be numbered in the order cited, multi-panel figures must be submitted as a single composite file, tables must not be embedded as figures or spreadsheet files, and tables must be created using the word processor's table function.
Reformat to Experimental Hematology & Oncology using Livewrite Premium

Recent Publications

Preclinical and clinical studies on CAR-NK cell therapy: latest update from 2025 ASH Annual Meeting

Hanxi Luo, Yiyang Ding, Xiangyu Zhao

10.1186/s40164-026-00780-6
View Publication

Hierarchies of resistance to DNA damage response inhibitors: from pathway restoration to replication stress tolerance

Valentina Morgera, Antonia Feola, Antonella Romano, Maria Vittoria Napoli, Armando Gabrielli, Vittorio Enrico Avvedimento, Antonio Porcellini, Antonio Pezone

10.1186/s40164-026-00779-z
View Publication

Inhibition of protein kinase CK2 remodels the tumor immune microenvironment and sensitizes lung cancer to PD-L1 blockade

Sijia Zhang, Lihua Luo, Yangang Qu, Yan Zong, Leichong Chen, Qianwen Li, Zhenyu Li, Jian Wang, Xiaohua Jie, Yun Xia, Bin Qu, Junyu Li, Chunwei Xu, Bingwen Zou, Hongqing Zhuang, Rui Meng

10.1186/s40164-026-00778-0
View Publication

ISX–TWIST1 reprograms CD47–inflammasome signaling to reshape the immune microenvironment in liver cancer

Li-Ting Wang, Ming-Hong Lin, Yi-Chuan Li, Shen-Nien Wang, Chee-Yin Chai, Jung-Mao Hsu, Shyh-Shin Chiou, Hsin-Ying Clair Chiou, Shau-Ku Huang, Mien-Chie Hung, Shih-Hsien Hsu

10.1186/s40164-026-00777-1
View Publication

Combining circulating tumor cell and circulating cell-free DNA analyses broadens clinical applicability of liquid biopsy in high grade serous tubo-ovarian carcinoma

Beatrice Cavina, Simona Corrà, Camelia Alexandra Coadă, Monica De Luise, Silvia Lemma, Sara Coluccelli, Antonio De Leo, Stella Di Costanzo, Francesco Mezzapesa, Giulia Girolimetti, Pierandrea De Iaco, Anna Maria Porcelli, Anna Myriam Perrone, Dario de Biase, Giuseppe Gasparre, Ivana Kurelac

10.1186/s40164-026-00774-4
View Publication

Frequently asked questions

How long does it take to publish?

Rapid turnaround time from submission to publication.

Reformat to Experimental Hematology & Oncology using Livewrite Premium

Is a cover letter required?

A cover letter is required and should explain why the manuscript should be published in Experimental Hematology & Oncology, address any issues relating to journal policies, declare potential competing interests, confirm all authors approved the submission, confirm the work has not been published or submitted elsewhere, and identify any special issue if applicable. Authors may also suggest preferred or non-preferred peer reviewers in the cover letter.

Reformat to Experimental Hematology & Oncology using Livewrite Premium

What are the publication costs?

Authors are asked to pay an open access fee for open access publication; article processing charges and book processing charges apply.

Reformat to Experimental Hematology & Oncology using Livewrite Premium

Research Topics

CAR-T cell therapy research Acute Myeloid Leukemia Research Cancer Immunotherapy and Biomarkers Lymphoma Diagnosis and Treatment Immune Cell Function and Interaction Immunotherapy and Immune Responses Immune cells in cancer Chronic Lymphocytic Leukemia Research Acute Lymphoblastic Leukemia research Multiple Myeloma Research and Treatments Epigenetics and DNA Methylation Myeloproliferative Neoplasms: Diagnosis and Treatment Ferroptosis and cancer prognosis Histone Deacetylase Inhibitors Research Virus-based gene therapy research Chronic Myeloid Leukemia Treatments Protein Degradation and Inhibitors Cancer Cells and Metastasis Hematopoietic Stem Cell Transplantation Cancer, Hypoxia, and Metabolism RNA modifications and cancer Lung Cancer Treatments and Mutations Cancer Genomics and Diagnostics Ubiquitin and proteasome pathways HER2/EGFR in Cancer Research

Related Journals

BN
BMC Nursing BioMed Central
JO
Journal Of Neuroengineering And Rehabilitation BioMed Central
JO
Journal Of Clinical Oncology LIPPINCOTT WILLIAMS & WILKINS
CC
Cancer Cell CELL PRESS
On
Oncogenesis Springer Nature
CA
Clinical And Translational Medicine Springer Science+Business Media